Levemir Innolet

Insulin detemir, the active ingredient in Levemir Innolet, is a long‑acting insulin analog presented as a solution for injection for subcutaneous use. It treats diabetes mellitus by providing basal insulin coverage in both type 1 and type 2 diabetes patients.

GNH USA supplies Levemir Innolet as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Levemir Innolet (insulin detemir) is a long‑acting insulin analog used to manage basal glucose control in diabetes. - Type 1 diabetes mellitus: provides steady basal insulin to reduce hyperglycemia. - Type 2 diabetes mellitus: supplements endogenous insulin to improve fasting glucose levels.

Levemir Innolet may be associated with a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Hypoglycemia: low blood glucose episodes, especially if dosing is mismatched with meals. - Injection site reactions: redness, swelling, or itching at the injection site. - Weight gain: gradual increase in body weight during therapy. - Lipodystrophy: localized changes in fat tissue at injection sites.

Serious or Rare Side Effects: - Allergic reactions: urticaria, angioedema, or anaphylaxis. - Severe hypoglycemia: seizures or loss of consciousness. - Edema: peripheral swelling, particularly in the lower extremities. - Hypertensive crisis: rare but reported in some patients.

Before initiating Levemir Innolet, consider the following precautions to ensure safe and effective use. - Blood glucose monitoring: perform regular self‑monitoring to adjust dose. - Renal impairment: assess kidney function, as insulin clearance may be reduced. - Hepatic impairment: use caution in patients with liver disease. - Concomitant medications: review other glucose‑lowering agents to avoid hypoglycemia. - Pregnancy and lactation: evaluate risk‑benefit; insulin is generally preferred but data are limited. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Levemir Innolet can interact with other medicines, altering its glucose‑lowering effect or increasing adverse risk.

Major Interactions (Avoid): - Sulfonylureas: combined use may cause severe hypoglycemia. - Meglitinides: additive glucose‑lowering effect increases hypoglycemia risk. - Beta‑blockers: may mask hypoglycemia symptoms.

Moderate Interactions (Monitor Closely): - ACE inhibitors: may enhance insulin sensitivity, requiring dose adjustment. - Corticosteroids: can raise blood glucose, potentially reducing insulin effectiveness. - Thyroid hormones: may increase insulin clearance, affecting control.